WuXi Biologics (“WuXi Bio”), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a strategic partnership with Toregem BioPharma, a biotech startup emerging from Kyoto University. This collaboration is set to accelerate the development of TRG035, a promising monoclonal antibody targeting USAG-1 for the treatment of congenital adentia, commonly known as tooth […]
CANbridge Pharmaceuticals said that it has dosed the first patient in a phase 1/2 trial of CAN103 in treatment-naïve patients in China having Gaucher disease (GD) Types I and III. The clinical trial of the recombinant human glucocerebrosidase enzyme replacement therapy is likely to enroll nearly 40 Gaucher disease patients. Gaucher disease is a lysosomal […]
Chinese CDMO WuXi Vaccines has signed a 20-year contract worth around $3bn with an undisclosed vaccine company to use a dedicated vaccine manufacturing facility in Ireland to supply commercial vaccine products manufactured from it for the global market. WuXi Vaccines, which is a joint venture between WuXi Biologics and Shanghai Hile Bio-technology, had announced an […]